MAX BioPharma, Inc. recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed journal, Cells. (https://www.mdpi.com/2073-4409/8/10/1297/pdf). Oxy210 is derived from the Company’s Oxysterol Therapeutics® platform of proprietary oxysterols. Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors that are commercially available or under clinical development. This new drug candidate is orally bioavailable, has favorable pharmacokinetic and safety profiles, is scalable, and was found to inhibit activation and pro-fibrotic activities of human liver stellate cells that drive fibrosis.
In a recent 16-week study…